Hadassah

Cell Cure Neurosciences Receives Grant of $1.33 Million From Israel's Office of the Chief Scientist

Wednesday, Aug 8 2012

Cell Cure Neurosciences Ltd., whose Chief Scientific Officer is Hadassah University Medical Center's Prof. Benjamin Reubinoff--Director of the its Human Embryonic Stem Cell Research Center--received a 1.3 million-dollar grant from Israel's Office of the Chief Scientist (OCS) to help finance its development of a treatment for age-related macular degeneration (AMD).

Cell Cure, established in 2005, manufactures diverse cell products, sourced from clinical-grade human embryonic stem cells. Its current programs include developing cells for the treatment of macular degeneration, Parkinson's disease, and cells potentially useful in treating multiple sclerosis. Cell Cure's plan for its cell-based product, OpRegen(R) includes filing an application to commence human clinical trials in 2013.

"We wish to thank the Office of the Chief Scientist for their participation in advancing this important new application of regenerative medicine," said Charles Irving, Chief Executive of Cell Cure. "We anticipate that OpRegen(R) will make a real difference in the quality of life of the aging population in many industrialized countries," he noted, "and hence it is a strategic investment for not only Israel, but the world as a whole."

AMD is a severe form of acute vision loss and the leading cause of blindness in older people. It affects that part of the retina which is most critical in everyday tasks, such as reading and recognizing faces. "I join with Dr. Irving in thanking OCS for its generous support in accelerating these advances in stem cell biology into the clinic," said Prof. Reubinoff.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Mar 22 2019

On World TB Day, March 24, Hadassah Celebrates Its Success Treating TB

Hadassah has been working on reducing the incidence of tuberculosis for nearly 100 years.

READ MORE ›
alt_text

Thursday, Mar 21 2019

Large Multinational Study Reveals Benefits of Dapagliflozin for Treatment of Diabetes

With 450 million adults worldwide suffering from diabetes today and an increase to more than 640 million expected by 2040, the need for a safe and effective treatment is ever more compelling.

READ MORE ›
alt_text

Tuesday, Mar 19 2019

Hadassah Genetic Research Demystifies Causes of Day Blindness in Families

Fifteen years ago, Prof. Dror Sharon joined the Hadassah Medical Organization’s Center for Retinal and Macular Degeneration to study the genetics of eye disease.

READ MORE ›
alt_text

Wednesday, Mar 13 2019

Saving Lives, Changing Lives at Hadassah-Neurim Youth Aliyah Village

Henrietta Szold was the mother of Youth Aliyah. The first young Jews who came on their own in the mid-1930s were fleeing Hitler. Many never saw their parents again, and they called her Ima. She met their boats, welcomed them, and became their staunch advocate in the no-frills pre-state Israel.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More